

Chairman & CEO Invests S\$600,000 as Warrant Conversions Gain Momentum

Key Highlights

- Chairman & CEO invested S\$600,000 in warrant exercise, signalling strong insider confidence
- Ongoing warrant conversions enabled by Company's delivery on strategic priorities and value creation since the 2024 rights issue
- Proceeds support U.S. expansion via the compounding pharmacy pathway

iX Biopharma Ltd. ("**the Company**") is pleased to announce that its Chairman & CEO Eddy Lee has exercised warrants amounting to S\$600,000, representing a strong vote of confidence in the Company's strategy, fundamentals and long-term growth trajectory.

This meaningful insider participation underscores management's conviction in the Company's future and reinforces alignment with shareholders.

As at 9 April 2026, a total of 17,565,084 warrants have been exercised, generating gross proceeds of approximately S\$1.05 million for the Company.

If all outstanding warrants are fully exercised, the Company will receive total gross proceeds of up to S\$3.45 million, representing a meaningful source of funding that would further strengthen its balance sheet and financial flexibility.

The warrants were issued to shareholders pursuant to the Company's 2024 rights cum warrants issue. Since then, the Company has delivered on its strategic priorities, reflected in a significant appreciation in its share price, supporting the ongoing conversion of warrants.

Proceeds from the conversion of warrants will support the Company's growth priorities, including its expansion into the United States market via supply through the compounding pharmacy pathway.

The Company is encouraged by the positive momentum in conversions and remains focused on delivering sustainable value for shareholders.

By Order of the Board

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor
Company Secretaries
9 April 2026

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.